🟢 Axsome Therapeutics is trading 4.52% up as RBC says Auvelity trends may be seasonal

Axsome Therapeutics is trading 4.52% up at $169.55 on October 15, rebounding after a sharp recent decline as RBC reiterated its Outperform rating and $295 target.

• RBC said weaker Auvelity prescription trends may reflect seasonality and sampling, not launch weakness.
• Expectations ahead of November 2 results may be beatable, while broader markets are under pressure.
• The analyst note—not a new company announcement—offers a company-specific reason for renewed buying interest.